Cytovac is a science driven biotech company also with capabilities of GMP production, running clinical trials, quality management and partnering R&D projects in the oncology segment. Clinical trials are executed in close collaboration with leading Scandinavian hospitals and CRO companies. The company employs a dedicated staff that has strong scientific experience within immunology, oncology and cell biology. Over the years, the company has built strong expertise within the fields of clinical research, cell-based production and quality control.
The company also hosts partnerships with other biotech companies drawing on Cytovac’s experience and facilities.
Cytovac’s mission is to develop new gentle and efficient ways to treat and survive cancer using the ALECSAT technology platform as stand alone or in combination with standard of care treatments or new immunotherapy treatments.
Cytovac A/S was privately founded in 2008 by Bent Alsø, Dr. Alexei Kirkin and Dr. Karine Dzhandzhougazyan. The technology behind the ALECSAT therapy is based on Dr. Kirkin and Dr. Dzhandzhougazyan’s long time scientific research.
Elements of the scientific hypothesis for this immunotherapy was initially developed in collaboration with the Danish Cancer Society. The Danish Cancer Society is still a collaboration partner on scientific projects.
In 2007, Dr. Karine Dzhandzhugazyan and Dr. Alexei Kirkin obtained the first patents for protection of the ALECSAT technology. The patent portfolio has continuously expanded since then.
The company is mainly financed by private investors.